Table 1.
Age group at baseline (in 1983) | Year | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | ||
Pharmaceutical intervention using metformin | ||||||||||||
Male | 25-29 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.42 | 0.41 |
30-34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.43 | 0.63 | 0.83 | 0.96 | |
35-39 | 0 | 0.24 | 0.23 | 0.23 | 0.30 | 0.45 | 0.44 | 0.86 | 1.41 | 1.36 | 1.65 | |
40-44 | 0.64 | 0.94 | 1.24 | 1.53 | 1.45 | 1.65 | 1.85 | 2.15 | 2.43 | 2.07 | 2.13 | |
Female | 25-29 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.28 | 0.27 |
30-34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.41 | 0.40 | |
35-39 | 0.35 | 0.34 | 0.66 | 1.29 | 1.14 | 1.12 | 1.32 | 1.29 | 1.46 | 1.40 | 1.53 | |
40-44 | 0.49 | 0.48 | 1.18 | 1.63 | 1.20 | 1.34 | 1.48 | 1.62 | 2.07 | 1.69 | 1.90 | |
Lifestyle intervention | ||||||||||||
Male | 25-29 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.62 | 0.61 |
30-34 | 0 | 0 | 0 | 0 | 0 | 0 | 0.22 | 0.64 | 0.85 | 0.97 | 1.09 | |
35-39 | 0.24 | 0.48 | 0.47 | 0.46 | 0.45 | 0.60 | 0.73 | 1.01 | 1.84 | 1.67 | 1.75 | |
40-44 | 0.64 | 1.10 | 1.24 | 1.53 | 1.45 | 1.65 | 2.06 | 2.15 | 2.86 | 2.40 | 2.46 | |
Female | 25-29 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.28 | 0.27 |
30-34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.41 | 0.40 | |
35-39 | 0.35 | 0.68 | 0.99 | 1.62 | 1.37 | 1.35 | 1.54 | 1.50 | 1.67 | 1.71 | 1.84 | |
40-44 | 0.49 | 0.48 | 1.18 | 1.63 | 1.37 | 1.51 | 1.81 | 1.94 | 2.38 | 1.94 | 2.02 |